Rylaze

Have resuscitation equipment and other agents available. Discontinue if serious hypersensitivity reactions occur. Monitor for pancreatitis; assess serum amylase and lipase levels if signs/symptoms develop. Discontinue if severe or hemorrhagic pancreatitis occurs. Withhold if mild pancreatitis until symptoms subside and amylase and/or lipase levels return to 1.5×ULN; may resume after resolution. Discontinue if a thrombotic event occurs and treat appropriately; consider resuming only if uncomplicated thrombosis. Hemorrhage. Consider appropriate replacement therapy if severe or symptomatic coagulopathy occurs. Monitor glucose, clinical examinations prior to treatment every 2–3 weeks and as clinically indicated. Evaluate bilirubin, transaminases prior to each cycle, at least weekly during therapy, and through 4 weeks after the last dose; monitor more frequently if abnormal liver tests develop. Monitor for signs/symptoms of hepatic veno-occlusive disease (VOD). Discontinue if serious liver toxicity, including VOD occurs. Advise females of reproductive potential to use effective non-hormonal contraception during and for 3 months after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).